Pharmanovia
Privately held: no public share price · United Kingdom
Assets
(3 total)
3Total Assets
2Approved
1Phase 3 / Filed
0Phase 1–2 / Early
4Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Approved | GABA-A receptorSmall molecule | Epilepsy | |
Solriamfetol(Sunosi) | Approved | Dopamine/norepinephrine transporterSmall molecule | Major Depressive DisorderNarcolepsyAttention Deficit Hyperactivity Disorder |
| Phase 3 | GABA-A receptorSmall molecule | Epilepsy |
Upcoming events
(7 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (2)
2027 (2)
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
29 March 2027FDA action dateLibervant (diazepam) buccal filmPDUFA date for the Libervant Type 9 NDA (ages 6 to 11)
US, FDA · Aquestive Therapeutics, Inc. (US licensee Eton Pharmaceuticals from 2026-10-14) · Source ↗
Recent
25 March 2025Topline resultSolriamfetolFOCUS Phase 3 of solriamfetol in adult ADHD (NCT05972044) met its primary endpoint
Axsome Therapeutics, Inc. · Source ↗
Financial reports
No financial reports recorded.